Company intelligence / Profile preview
Biological E. Limited
- Ownership
- Private
- Employees
- ~2500
- Development stage
- Commercial
Overview
Biological E. Limited has a broad commercial portfolio of vaccines with over 2 billion doses supplied in the last decade to more than 100 countries. It holds seven WHO pre-qualified vaccines and was among the first Indian companies to develop and supply low-cost pentavalent and COVID vaccines globally[6][1][3]. Its COVID vaccine Corbevax was developed in partnership with Baylor College of Medicine/Dynavax Technologies[2].
- Therapeutic areas
- Infectious Diseases
- Modalities
- Vaccines (bacterial toxoids, polysaccharide conjugates, cell culture viral vaccines)recombinant proteins
- Industry
- Pharma
Drug pipeline
10 assets9 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Biological E. Limited.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Biological E. Limited.